EML4 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Alectinib is a tyrosine kinase inhibitor targeting ALK and ROS1 receptors. It blocks the ATP-binding site, inhibiting receptor autophosphorylation and downstream signaling pathways, ultimately inhibiting cell proliferation and survival in ALK-positive and ROS1-positive cancer cells. | ||||||
Lorlatinib | 1454846-35-5 | sc-507437 | 5 mg | $135.00 | ||
Lorlatinib inhibits ALK, ROS1, and other kinases. It can cross the blood-brain barrier, making it effective against brain metastases. It binds to the ATP-binding pocket of the targeted kinases, disrupting their signaling cascades. | ||||||
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | 1032900-25-6 | sc-505041 | 1 mg | $230.00 | ||
Ceritinib targets ALK by competing with ATP for binding to the kinase domain. It inhibits ALK-mediated signaling, resulting in decreased cell proliferation and increased apoptosis in ALK-positive cancer cells. | ||||||
TAE684 | 761439-42-3 | sc-364626 sc-364626A | 5 mg 50 mg | $184.00 $969.00 | 2 | |
TAE-684 selectively targets ALK by blocking its kinase activity. It interferes with ATP binding to ALK's kinase domain, preventing downstream signaling and inhibiting tumor cell growth. | ||||||